High level of CXCR4 in triple-negative breast cancer specimens associated with a poor clinical outcome

Acta Medica Okayama

Volumn 67, Issue 6, 2013, Pages 369-376

  Yu, Shaonan ^a   Wang, Xiaozhen ^b   Liu, Guifeng ^a,b   Zhu, Xuewei ^a   Chen, Yan ^a  

^a JILIN UNIVERSITY   (China)

^b PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

Author keywords

CXCR4; Immunohistochemical staining; Triple negative breast cancer

Indexed keywords

CHEMOKINE RECEPTOR CXCR4; CXCR4 PROTEIN, HUMAN; TUMOR MARKER;

ARTICLE; BIOPSY; BREAST; FEMALE; HUMAN; KAPLAN MEIER METHOD; METABOLISM; MIDDLE AGED; PATHOLOGY; PREDICTIVE VALUE; PROGNOSIS; RETROSPECTIVE STUDY; TREATMENT OUTCOME; TRIPLE NEGATIVE BREAST CANCER;

BIOPSY; BREAST; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RECEPTORS, CXCR4; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; TRIPLE NEGATIVE BREAST NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84891329941     PISSN: 0386300X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Rouzier R, Perou CM, Symmans WF, Ibrahim N, Cristofanilli M Anderson K, Hess KR, Stec J, Ayers M, Wagner P, Morandi P. Fan C, Rabiul I, Ross JS, Hortobagyi GN and Pusztai L. Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res (2005) 11. 5678-5685.
2. Carey LA, Dees EC, Sawyer LR, Gatti L, Moore DT, Collichio F. Ollila DW, Sartor CI, Graham ML and Perou CM. The triple negative paradox. Primary tumor chemosensitivity of breast cancer subtypes. Clin Can Res (2007) 13. 2329-2334.
3. . Symmans WF, Gonzalez-Angulo AM, Hennessy B, Green M Cristofanilli M, Hortobagyi GN and Pusztai L. Response to Neoadjuvant Therapy and Long-Term Survival in Patients With Triple-Negative Breast Cancer. J Clin Oncol (2008) 26. 1275-1281
4. Pinilla SM, Honrado E, Hardisson D, Benitez J and Palacios J. Caveolin-1 expression is associated with a basal-like phenotype in sporadic and hereditary breast cancer. Breast Cancer Res Treat (2006)99. 85-90.
5. Li H, Cherukuri P, UN, Cowling V, Spinella M, Cole M, Andrew K. Godwin AK, Wells W and DiRenzo J. Nestin is expressed in the basal/myoepithelial layer of the mammary gland and is a selective marker of basal epithelial breast tumors. Cancer Res (2007)67. 501-510.
6. Siziopikou K and Cobleigh M. The basal subtype of breast carcinomas may represent the group of breast tumors that could benefit from EGFR-targeted therapies. Breast (2007) 16. 104-107.
7. Hoadley KA, Weigman VJ, Fan C, Sawyer LR, He X, Troester MA, Sartor CI, Rieger-House T, Bernard PS, Carey LA and Perou CM. EGFR associated expression profiles vary with breast tumor subtype. BMC Genomics (2007) 8. 258.
8. Moyano J, Evans J, Chen F, Lu M, Werner ME, Yehiely F. Turbin D, Nielsen TO, Perou CM and Cryns VL. Alpha B-Crystallin is a novel oncoprotein that predicts poor clinical outcome in breast cancer. J Clin Invest (2006) 116. 261-270.
9. Chelouche-Lev D, Kluger H, Berger A, Rimm DL and Price JE. Alpha B-crystallin as a marker of lymph node-involvement in breast carcinoma. Cancer (2004) 100. 2543-2548
10. Trihia H, Murray S, Price K, Gelber RD, Golouh R, Goldhirsch A. Coates AS, Collins J, Castiglione-Gertsch M, Gusterson BA. and International Breast Cancer Study Group. Ki-67 expression in breast carcinoma. its association with grading systems, clinical parameters, and other prognostic factors-a surrogate marker? Cancer (2003) 97. 1321-1331.
11. Nakagawa M, Bando Y, Nagao T, Morimoto M, Takai C, Ohnishi T, Honda J, Moriya T, Izumi K, Takahashi M, Sasa M and Tangoku A. Expression of p53, Ki-67, E-cadherin, N-cadherin and TOP2A in triple-negative breast cancer. Anticancer Res (2011) 31. 2389-2393.
12. Muller A, Homey B, Soto H, Ge N, Catron D, Buchanan ME, McClanahan T, Murphy E, Yuan W, Wagner SN, Barrera JL Mohar A, Verastegui E and Zlotnik A. Involvement of chemokine receptors in breast cancer metastasis. Nature (2001) 410. 50-56.
13. Lee BC, Lee TH, Avraham S and Avraham HK. Involvement of the chemokine receptor CXCR4 and its ligand stromal cell-derived factor 1a in breast cancer cell migration through human brain microvascular endothelial cells. Mole Cancer Res (2004) 2. 327-338.
14. Liang Z, Yoon Y, Votaw J, Goodman MM, Williams L and Shim H. Silencing of CXCR4 blocks breast cancer metastasis. Cancer Res(2005) 65. 967-971
15. Lapteva N, Yang A, Sanders D, Strube RW and Chen SY. CXCR4 knockdown by small interfering RNA abrogates breast tumor growth in vivo. Cancer Gene Ther (2005) 12. 84-89.
16. Smith MCP, Luker KE, Garbow JR, Prior JL, Jackson E, Piwnica-Worms D and Luker GD. CXCR4 regulates growth of both primary and metastatic breast cancer. Cancer Res (2004) 64. 8604-8612.
17. Holm N, Byrnes K, Li B, Turnage R, Abreo F, Mathis J and Chu QD. Elevated levels of chemokine receptor CXCR4 in HER-2 negative breast cancer specimens predict recurrence. J Surg Res (2007) 141. 53-59.
18. Holm N, Abreo F, Johnson L, Li B and Chu QD. Elevated chemokine receptor CXCR4 expression in primary tumors following neoadjuvant chemotherapy predicts poor outcomes for patients with locally advanced breast cancer (LABC). Breast Cancer Res Treat (2009) 113. 293-299.
19. Elston CW and Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer experience from a large study with long-term follow-up. Histopathology (1991) 19. 403-410.
20. Fitzgibbons PL, Page DL, Weaver D, Thor AD, Allred DC, Clark GM, Ruby SG, O'Malley F, Simpson JF, Connolly JL, Hayes DF, Edge SB, Lichter A and Schnitt SJ. Prognostic factors in breast cancer. College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med (2000) 124. 966-978.
21. Allred DC, Harvey JM, Berardo M, Clark GM. Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol (1998) 11. 155-168.
22. Wollf AC, Hammond ME, Schwartz JN, Hagerty KL, D Allred C Cote RJ, Dowsett M, Fitzgibbons PL, Hanna WM, Langer A, McShane LM, Paik S, Pegram MD, Perez EA, Press MF, Rhodes A, Sturgeon C, Taube SE, Tubbs R, Vance GH, van de Vijver M Wheeler TM, Hayes DF. and American Society of Clinical Oncology/College of American Pathologists. American Society of Clinical Oncology/College of American Pathologists guideline recommendation for human epidermalgrowth factor 2 testing in breast cancer. Arch Pathol Lab Med (2007) 131. 18-43.
23. Early Breast Cancer Trialists' Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival. an overview of the randomised trials. Lancet (2005) 365. 1687-1717.
24. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I, Gianni L, Baselga J, Bell R, Jackisch C Cameron D, Dowsett M, Barrios CH, Steger G, Huang CS Andersson M, Inbar M, Lichinitser M, Lang I, Nitz U, Iwata H Thomssen C, Lohrisch C, Suter TM, Ruschoff J, Suto T. Greatorex V, Ward C, Straehle C, McFadden E, Dolci MS Gelber RD. and Herceptin Adjuvant (HERA) Trial Study Team Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med (2005) 353. 1659-1672.
25. Romond EH, Perez EA, Bryant J, Suman VJ, Geyer Jr CE, Davidson NE, Tan-Chiu E, Martino S, Paik S, Kaufman PA, Swain SM, Pisansky TM, Fehrenbacher L, Kutteh LA, Vogel VG Visscher DW, Yothers G, Jenkins RB, Brown AM, Dakhil SR Mamounas EP, Lingle WL, Klein PM, Ingle JN and Wolmark N. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med (2005) 353. 1673-1684.
26. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M Baselga J and Norton L. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overex-presses HER2. N Engl J Med (2001) 344. 783-792.
27. Chu QD, Panu L, Holm NT, Li BD, Johnson LW and Zhang S. High chemokine receptor CXCR4 level in triple negative breast cancer specimens predicts poor clinical outcome. J Surg Res (2010) 159 689-695